The Japan cell and gene therapy market size was valued at USD 727 Million in 2024. Looking forward, IMARC Group estimates the market to reach USD 2,016 Million by 2033, exhibiting a CAGR of 12% from 2025-2033. The market in Japan is driven by advancements in biotechnology, a growing focus on personalized medicine, and increased government support for regenerative therapies. The widespread adoption of novel cell and gene therapies is further accelerated by an aging population, the increasing frequency of hereditary and chronic diseases, and significant investments in research and development (R&D).

https://www.imarcgroup.com/japan-cell-gene-therapy-market